Document Detail

Haploidentical bone marrow transplants for hematological malignancies using non-myeloablative conditioning therapy and post-transplant immunosuppression with cyclophosphamide: results from a single Australian centre.
MedLine Citation:
PMID:  22646924     Owner:  NLM     Status:  Publisher    
Background:  HLA haploidentical bone marrow transplantation is a treatment option in patients with hematological malignancies who have no available HLA matched donor, but is limited by conditioning regimen toxicity, graft failure, relapse and graft versus host disease. Aims:  To demonstrate safety and efficacy of haploidentical bone marrow transplantation with nonmyeloablative conditioning and high-dose post-transplant cyclophosphamide in adult patients with leukaemia or lymphoma. Methods:  12 patients, median age of 51 years, underwent transplantation with T cell replete bone marrow from a haplotype matched relative. The conditioning regimen consisted of cyclophosphamide, fludarabine, and low-dose TBI. Post-transplant immunosuppression consisted of a single dose of cyclophosphamide 50 mg/kg on day 3, followed by oral tacrolimus and mycophenolatemofetil. Outcomes reported are overall survival, engraftment and chimerism, toxicity, and clinical outcome. Results:  All patients had neutrophil recovery (median 14.5 days), and 11 of 12 had platelet engraftment (median 17 days). Two patients had autologous reconstitution. Seven of 9 assessable patients had complete donor chimerism. Four patients had grade II-III GvHD, and none had grade IV GvHD. Four patientsdeveloped limited stage chronic GvHD. Five patients with AML relapsed. Two patients died of non-relapse causes, both from other malignancies, and 5 patients remain alive and relapse free. Median overall survival was324 days (range 88-1163). Conclusion:  This regimen is feasible and well-tolerated in older patients with high risk leukemia or lymphoma, with minimal short-term toxicity, and low rates of GVHD. The proportion of disease-free survivors indicates a graft versus malignancy effect is present in survivors. © 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians.
Ian A Bilmon; John Kwan; David Gottlieb; Ian Kerridge; Mary McGurgan; Gillian Huang; Biju George; Mark Hertzberg; Kenneth F Bradstock
Related Documents :
10536974 - Benchmarking organ procurement organizations: a national study.
15600114 - "robin hood" of techno-turkey or organ trafficking in the state of ethical beings.
24994754 - High-emergency waiting list for lung transplantation: early results of a nation-based s...
25017074 - Cardiac and pulmonary issues in lt assessment candidates.
2206504 - Transtympanic endoscopic findings in patients with otitis media with effusion.
9917824 - Cryopreservation and transplantation of dog trachea.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-30
Journal Detail:
Title:  Internal medicine journal     Volume:  -     ISSN:  1445-5994     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101092952     Medline TA:  Intern Med J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians.
Blood and Marrow Transplant Service, Westmead Hospital, Sydney, New South Wales, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Photo-degradable polyurethane self-assembled nanoparticles for photocontrollable release.
Next Document:  Essential Fatty Acids: Food for mind and body.